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Introduction: The “International Nonproprietary Name (INN) pre-
scribing project” in Belgium aimed to operationalize electronic INN 
prescribing for outpatient care in daily medical practice and medical 
informatics.
Patients (or Materials) and Methods: The operationalization process 
consisted of 3 phases: (1) expert consultation; (2) review by regula-
tory authorities; and (3) test phase with stakeholders and end-users.
Results: The INN prescribing project resulted in: (1) operational 
rules for electronic INN prescribing; (2) the classification of the thera-
peutic arsenal, according to the operational rules; and (3) a refer-
ence database to be implemented in commercial medical software. 
The operational rules for electronic INN prescribing define valid 
INN groups as sets of equivalent medicinal products, described by 3 
elements: the therapeutic moiety (the active part of the therapeutic 
ingredient) or combination of therapeutic moieties, the strength (with 
standardized denominators), and the method of administration (with 
simplified but standardized options). The operational rules also define 
2 categories of exemptions for INN prescribing: INN groups where 
the first choice of treatment should be continued throughout the 
therapy period (NO SWITCH) and medicinal product groups not 
suitable for INN prescribing (NO INN).
Conclusion: Operationalizing INN prescribing for electronic pre-
scribing was a difficult yet feasible assignment. The INN prescribing 
project resulted into universally applicable operational rules and a 
corresponding classification of the therapeutic arsenal and reference 
database. These outcomes can be used by other countries planning 
to implement electronic INN prescribing.
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Introduction: Traditionally, the training in clinical pharmacology 
concentrated primarily on teaching of rational drug application for 
students and clinical therapists. Clinical medicines development is 
another important field of clinical pharmacology that requires a 
different training approach closely following the emergence of new 
scientific knowledge.
Results: A modern life-long learning concept for clinical pharma-
cologists must take into consideration the emerging new technologies 
of medicines development and application. The appearance of highly 
sensitive and noninvasive technologies to measure pharmacokinetic 
and pharmacodynamic parameters makes possible drug investigation 
in humans using extremely low doses without substantial danger for 
the volunteers at the very early stage of medicines development. These 
so-called Phase 0 trials permit to enrich the animal results with human 
pharmacologic data before initiating the classical human Phase I dose 
escalation study requiring more extensive animal toxicology. In early 
clinical development of new types of biological medicinal agents, 
drug-containing nanoparticles, medical device and drug combina-
tions, new pharmaceutical formulations routinely require a team of 
clinicians and natural scientists to perform jointly the complex tasks 
of the early learning phase of clinical medicines development. Beside 
profound knowledge in their primary clinical specialty, the new gen-
eration of clinical pharmacologists needs extensive additional train-
ing in the new methodologies of drug discovery, molecular biology, 
immunology, translational medicine, etc. for efficiently functioning 
in a multidisciplinary team.
Conclusion: At the Semmelweis University, the teaching of a reor-
ganized postgraduate training plan for clinical pharmacologists was 
initiated applying the principles outlined above. On the basis of our 
experience, an outline for a new national curriculum of clinical phar-
macology has been developed, which will be presented. The new 
plan takes over several topics and concepts worked out during the 
harmonization of pharmaceutical medicine education in Europe by 
PharmaTrain. A certain overlap in pharmaceutical medicinal and clini-
cal pharmacological curricula is desired, considering that the optimal 
clinical application of new types of medicines needs much more basic 
scientific knowledge than the use of traditional medicinal agents.
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Introduction: Drug manufacturers developed “evergreening strate-
gies” to compete with generic medication after patent termination. 
These include marketing of slightly modified follow-on drugs (slow-
release formulations, single isomer chiral molecules, active metabo-
lites, or structural analogues/combinations of original patented 
drugs) and offering high rebates to hospitals that use brand-name or 
evergreening drugs. The Geneva University Hospitals (HUG) and the 
Geneva community have different rules indeed. Drug prices are nego-
tiated and prescriptions restricted at HUG, while prices are fixed and 
prescriptions unrestricted in the community. We examine the impact 
of listing these drugs in the hospital-restrictive drug formulary (RDF) 
on the health care system as a whole (“spillover effect”).
Patients (or Materials) and Methods: We linked hospital and com-
munity pharmacy invoice office data in the Swiss canton of Geneva 
to calculate utilization of 8 follow-on drugs in defined daily doses 
between 2000 and 2008. This database includes > 73% of the total 
of insured patients. To examine the financial spillover effect, we cal-
culated a monthly follow-on drug market share in DDDs for medica-
tions prescribed by hospital physicians dispensed in the community 
(eg, at hospital discharge, in outpatient clinics) in comparison to 
drugs prescribed by physicians in the community. The spillover effect 
dynamic was analyzed under robust time series analysis using autore-
gressive integrated moving average (ARIMA) models.
